Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
07/2012
07/12/2012US20120177669 Phosphopeptides as melanoma vaccines
07/12/2012US20120177666 Anti-tgf-beta receptor ii antibodies
07/12/2012US20120177659 Methods and compositions for treating and diagnosing diseases
07/12/2012US20120177658 Methods of treatment using an anti il b50 antibody
07/12/2012US20120177656 Compounds and Methods for the Modulation of Sulfilimine Bond Formation
07/12/2012US20120177652 Bispecific binding agents for modulating biological activity
07/12/2012US20120177649 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
07/12/2012US20120177643 Human cdr-grafted antibody and antibody fragment thereof
07/12/2012US20120177641 Gefitnib Sensitivity-Related Gene Expression and Products and Methods Related Thereto
07/12/2012US20120177640 Optimizing the production of antibodies
07/12/2012US20120177636 Carbohydrate-containing pan cancer marker
07/12/2012US20120177634 Demethylpenclomedine analogs and their use as anti-cancer agents
07/12/2012US20120177628 Arginase formulations and methods
07/12/2012US20120177626 Hdl comprising a therapeutic agent and use in therapy
07/12/2012US20120177621 Enhancement of Allogeneic Hematopoietic Stem Cell Transplantation
07/12/2012US20120177610 Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin , and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin / Apo/Human Albumin/A1AT and all new found proteins
07/12/2012US20120177604 Formation of hydrogel in the presence of peroxidase and low concentration of hydrogen peroxide
07/12/2012US20120177602 Dissolution aids for oral peptide delivery comprising a biguanide
07/12/2012US20120177599 Compositions and methods for treatment, diagnosis and prognonis of mesothelioma
07/12/2012US20120177598 Compositions and Methods for Immunomodulation in an Organism
07/12/2012US20120177596 METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
07/12/2012US20120177595 Multimeric il-15 soluble fusion molecules and methods of making and using same
07/12/2012US20120177593 Synthesis of dendrimer conjugates
07/12/2012US20120177580 Metal Abstraction Peptide (MAP) Tag and Associated Methods
07/12/2012US20120177579 Metal Abstraction Peptide (MAP) Tag and Associated Methods
07/12/2012US20120177578 Compositions, methods, and systems comprising fluorous-soluble polymers
07/12/2012US20120177575 Fas (apo-1,cd95) targeted platforms for intracellular drug delivery
07/12/2012US20120177567 Methods of Treating Pediatric Acute Lymphoblastic Leukemia with an Anti-CD22 Immunotoxin
07/12/2012US20120177566 Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells
07/12/2012DE102011008352A1 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate 5 - ([1,2,3] triazol-4-yl) -7H-pyrrolo [2,3-d] pyrimidine derivatives
07/12/2012DE102011008070A1 Use of tocotrienol for prevention, aftercare, treatment or auxiliary treatment of proliferative diseases, inflammatory diseases, heart disease, diseases of nervous system, and aftercare of surgical interventions or mitigation of swelling
07/12/2012CA2834968A1 Methods of making liposomes, liposome compositions made by the methods, and methods of using the same
07/12/2012CA2834101A1 Novel indole or indazole derivative or salt thereof
07/12/2012CA2824277A1 Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
07/12/2012CA2824028A1 Novel ureas for the treatment and prevention of cancer
07/12/2012CA2824013A1 Novel bicyclic compound or salt thereof
07/12/2012CA2823969A1 2,4-diamino-6,7-dihydro-5h-pyrrolo[2,3]pyrimidine derivatives as fak/pyk2 inhibitors
07/12/2012CA2823935A1 Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
07/12/2012CA2822481A1 A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
07/12/2012CA2822300A1 Compositions and methods of aloe polysaccharides
07/11/2012EP2474617A1 Mir for treating neo-angiogenesis
07/11/2012EP2474557A2 Anti-CD79b antibodies and immunoconjugates and methods of use
07/11/2012EP2474552A1 New saccharide mimics and their use as inhibitors of angiogenesis and metastasis formation
07/11/2012EP2474550A1 Derivatives of Englerin for the treatment of cancer
07/11/2012EP2474546A1 Thiophene-carboxamides useful as inhibitors of protein kinases
07/11/2012EP2474545A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
07/11/2012EP2474541A1 Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
07/11/2012EP2474327A1 Microdosing of ultrasound contrast agents
07/11/2012EP2474315A1 Immunity inducer
07/11/2012EP2473530A1 Monoclonal antibodies against gonadotropin-releasing hormone receptor
07/11/2012EP2473529A1 Clec14a inhibitors
07/11/2012EP2473513A1 Compounds as tyrosine kinase modulators
07/11/2012EP2473510A1 Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
07/11/2012EP2473509A1 Kinase inhibitors, prodrug forms thereof and their use in therapy
07/11/2012EP2473506A2 Compounds and compositions for treating cancer
07/11/2012EP2473505A1 Pyrazinylpyridines useful for the treatment of proliferative diseases
07/11/2012EP2473504A2 Heterocyclic compounds for the inhibition of pask
07/11/2012EP2473501A1 Compounds as tyrosine kinase modulators
07/11/2012EP2473500A2 Benzimidazole derivatives
07/11/2012EP2473499A1 Bipyridines useful for the treatment of proliferative diseases
07/11/2012EP2473495A1 Pharmaceutical compounds
07/11/2012EP2473199A1 Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders
07/11/2012EP2473197A2 Drug activation system
07/11/2012EP2473186A1 Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
07/11/2012EP2473182A2 Targeted delivery using tissue-specific peptidomimetic ligands
07/11/2012EP2473168A1 Pharmaceutical formulations for indibulin
07/11/2012EP2473054A1 Compositions and methods for treatment of leukemia
07/11/2012EP2473051A1 Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
07/11/2012EP2473049A1 Bruton's tyrosine kinase inhibitors
07/11/2012EP2473041A1 Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
07/11/2012EP2415870A9 Rnai molecule for thymidylate synthase and use thereof
07/11/2012EP2233501B1 Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof
07/11/2012EP2121039B1 Nanoparticle clusters and methods for forming same
07/11/2012EP2089053B1 Hpv antigen fusion protein vaccine compositions and uses thereof
07/11/2012EP2076132B1 P-toluene sulfonic acid salt of 5-amino-3-(2'-o-acetyl-3'-deoxy-beta -d-ribofuranosyl)-3h-thiazole [4, 5-d]pyrimidine-2-one and methods for preparation
07/11/2012EP2023922B1 Triazole derivatives ii
07/11/2012EP1973883B1 Novel compounds and methods for their production
07/11/2012EP1971588B1 Tiglien-3-one derivatives
07/11/2012EP1960434B1 Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
07/11/2012EP1945265B1 Antiproliferative combination comprising cyc-682 and a cytotoxic agent
07/11/2012EP1885380B1 Sodium meta-arsenite for use in the treatment of metastatic neoplastic diseases
07/11/2012EP1762242B1 MALIGNANT TUMOR INHIBITOR CONTAINING Des A FIBRIN
07/11/2012EP1731160B1 Cancer metastasis inhibitory composition
07/11/2012EP1590360B1 Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases
07/11/2012EP1472224B1 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
07/11/2012EP1471056B1 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
07/11/2012EP1470121B1 Pyrimidine derivatives as rho-kinase inhibitors
07/11/2012CN1900074B Substituted oxazolidinones and their use in the field of blood coagulation
07/11/2012CN1688532B Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
07/11/2012CN102575300A CSTF2 for target genes of lung cancer therapy and diagnosis
07/11/2012CN102575254A Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
07/11/2012CN102575236A Inhibition of histone acetyltransferases by CTK7A and methods thereof
07/11/2012CN102575230A Preserved compositions of activated nk cells and methods of using the same
07/11/2012CN102574925A Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
07/11/2012CN102574917A Pharmaceutical composition containing anti-HB-EGF antibody as active ingredient
07/11/2012CN102574916A Human recombinant monoclonal antibody that specifically binds to VCAM-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells
07/11/2012CN102574890A Certain chemical entities, compositions, and methods
07/11/2012CN102574866A Camptothecin derivatives
07/11/2012CN102574863A Heterocyclic compounds as JANUS kinase inhibitors
07/11/2012CN102574857A Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors
1 ... 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 ... 2211